Search
Stifel's Tim Opler discusses how the sector's recent rally is affecting things on the investment banking side
He comments on IPOs, fundraising, M&A, and China. Coverage brought to you by
5 hours ago
BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues
He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors....
Jun 16
Stifel's Tim Opler shares feedback from SF Healthcare Week and thoughts on biotech's year ahead from a banking perspective
Tim Opler discusses the M&A environment, IPO windown, PIPE and crossover financings, and more.
Jan 22, 2024
.png){kind=logo}
